A first-in-human trial of the anti-Ang-2 monoclonal antibody LY3127804 in patients with advanced solid tumours demonstrated acceptable safety and preliminary biological activity, supporting the feasibility of Ang-2–targeted therapeutics and suggesting potential applicability to ARDS populations in future studies [24]. This evidence concerns the gene ANGPT2 and acute respiratory distress syndrome.